OBX starts placebo-controlled trial of minor cannabinoid formulations

OBX starts placebo-controlled trial of minor cannabinoid formulations

Open Book Extracts has started a placebo-controlled trial of minor cannabinoid formulations to improve relaxation and calmness.

The most common mental health disorder in the world is anxiety. In 2017 an estimated 284 million people had experienced anxiety disorders, with women being diagnosed twice as many as men. To address this market need, OBX developed and tested distinct formulas designed to help people unwind relaxation and/or clear mind calmness Based on scientific literature and real-world feedback, six active ingredients were selected and formulated to promote two distinct mood states: relaxation and calmness. The selected cannabinoids were CBD, CBG, CBC and CBDV, and the polyphenols were Quercetin and Curcumin. Candidates were selected by showing evidence of anxiolytic-like effects with minimal sedative-like effects. Secondary criteria included alterations in mood, sleep, and cognitive performance.

A double-blinded, placebo-controlled evaluation is being conducted to determine the efficacy of these products. Self-reported outcomes will be collected and reported on relaxation and stress. The study will be virtual with no in-person visits. The anonymous tracking of the real-time experiences of study products will be a feature of a secure online software service.

Andrea Baillo, OBX chief scientific officer, stated that too many people struggling with mental health issues struggle with access to effective, non-pharmaceutical solutions. The OBX Relaxation StudyOBX Relaxation Study will examine different formulations of cannabinoids and other bioactives to better understand their ability to improve relaxation, stress, and overall well-being. This is the place where money is raised, M&A starts, and companies meet key partners. On April 11 -- 12 at Fontainebleau Miami Beach Hotel in Florida.